If you have a pulse on the bro-verse, you already know that everyone’s hot to trot for Retatrutide Eli Lilly’s next-gen triple agonist drug (GLP-1, GIP, glucagon). It suppresses appetite, improves insulin sensitivity and insulin production, and increases energy expenditure and fat burning. The hype has been insane, and honestly, the early data looks like it could back it up.